Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price

Confirmatory Trial Seeks To Show Survival Advantage

 
• By Mandy Jackson
  
Abstract futuristic human lungs
Testing for KRAS G12C mutations is rising but Mirati will push for improvements • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip